DE60028996D1 - Behandlung von krebs durch erhöhung des malonyl-coa-spiegels - Google Patents

Behandlung von krebs durch erhöhung des malonyl-coa-spiegels

Info

Publication number
DE60028996D1
DE60028996D1 DE60028996T DE60028996T DE60028996D1 DE 60028996 D1 DE60028996 D1 DE 60028996D1 DE 60028996 T DE60028996 T DE 60028996T DE 60028996 T DE60028996 T DE 60028996T DE 60028996 D1 DE60028996 D1 DE 60028996D1
Authority
DE
Germany
Prior art keywords
fatty acid
inhibition
cpt
fas
malonyl coa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60028996T
Other languages
English (en)
Other versions
DE60028996T2 (de
Inventor
S Pizer
A Townsend
P Kuhajda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE60028996D1 publication Critical patent/DE60028996D1/de
Publication of DE60028996T2 publication Critical patent/DE60028996T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60028996T 1999-11-12 2000-11-13 Behandlung von krebs durch erhöhung des malonyl-coa-spiegels Expired - Fee Related DE60028996T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16476599P 1999-11-12 1999-11-12
US16476899P 1999-11-12 1999-11-12
US164765P 1999-11-12
US164768P 1999-11-12
PCT/US2000/031067 WO2001034145A1 (en) 1999-11-12 2000-11-13 Treating cancer by increasing intracellular malonyl coa levels

Publications (2)

Publication Number Publication Date
DE60028996D1 true DE60028996D1 (de) 2006-08-03
DE60028996T2 DE60028996T2 (de) 2007-02-08

Family

ID=26860829

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60028996T Expired - Fee Related DE60028996T2 (de) 1999-11-12 2000-11-13 Behandlung von krebs durch erhöhung des malonyl-coa-spiegels

Country Status (12)

Country Link
US (1) US20020187534A1 (de)
EP (1) EP1227810B8 (de)
JP (1) JP2003513920A (de)
KR (4) KR20090130151A (de)
AT (1) ATE330598T1 (de)
AU (3) AU784495B2 (de)
CA (1) CA2391277A1 (de)
DE (1) DE60028996T2 (de)
DK (1) DK1227810T3 (de)
ES (1) ES2267587T3 (de)
PT (1) PT1227810E (de)
WO (1) WO2001034145A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481640T1 (de) * 2000-11-27 2010-10-15 Minerva Biotechnologies Corp Diagnostika, drogenscreening und behandlung für krebs
WO2003037323A2 (en) * 2001-10-26 2003-05-08 MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction
EA007029B1 (ru) 2002-02-08 2006-06-30 Джон Хопкинс Юниверсити Скул Оф Медсин Стимуляция срт-1 как средство уменьшения веса
CN101633650A (zh) * 2002-07-01 2010-01-27 法斯根有限责任公司 新化合物、包含该化合物的药物组合物及该化合物的应用方法
JP2006507306A (ja) * 2002-10-31 2006-03-02 ファスゲン，インク． 脂肪酸シンターゼ阻害剤による癌の発生を阻害する方法
JP2006519229A (ja) 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ 視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節
US8071645B2 (en) 2003-06-12 2011-12-06 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
ITMI20040230A1 (it) * 2004-02-12 2004-05-12 Defiante Farmaceutica Lda Composti ad attivita' antitumorale
JP2008539238A (ja) * 2005-04-28 2008-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 治療用二機能性化合物
AU2006242667A1 (en) 2005-05-02 2006-11-09 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition
EP2018873A4 (de) * 2006-04-07 2009-12-09 Japan Found Cancer Mittel zur prophylaxe/behandlung von krebs
WO2008106796A1 (en) * 2007-03-08 2008-09-12 University Health Network Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity
WO2008109991A1 (en) 2007-03-09 2008-09-18 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
US20090053804A1 (en) * 2007-07-27 2009-02-26 Vesta Therapeutics, Inc. Methods of reducing intracellular fats from mammalian cells
WO2009015485A1 (en) * 2007-08-01 2009-02-05 University Health Network Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
US8394377B2 (en) 2008-02-21 2013-03-12 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
WO2010008554A2 (en) 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
JP5317919B2 (ja) * 2009-10-05 2013-10-16 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
CN107660213B (zh) 2015-02-10 2023-01-13 米纳瓦生物技术公司 人源化抗MUCl＊抗体
JP6811489B2 (ja) * 2016-10-17 2021-01-13 学校法人慶應義塾 未分化幹細胞除去剤、及び未分化幹細胞除去方法
US20220244245A1 (en) * 2019-04-15 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) A method of profiling the energetic metabolism of a population of cells
CN113549702A (zh) * 2021-09-14 2021-10-26 北京大学第三医院（北京大学第三临床医学院） 一种人脂肪酸代谢关键酶基因检测方法以及试剂盒
CN113604573A (zh) * 2021-09-14 2021-11-05 北京大学第三医院（北京大学第三临床医学院） 一种使用至少八种脂肪酸代谢关键酶基因检测方法以及试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
KR100325766B1 (ko) * 1992-07-24 2002-07-27 더 존스 홉킨스 유니버시티 암치료를위한지방산합성억제제를함유하는약학조성물
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Also Published As

Publication number Publication date
AU2006203005A1 (en) 2006-08-10
KR20090130151A (ko) 2009-12-17
EP1227810B1 (de) 2006-06-21
KR20070106648A (ko) 2007-11-02
DK1227810T3 (da) 2006-10-23
EP1227810A1 (de) 2002-08-07
JP2003513920A (ja) 2003-04-15
DE60028996T2 (de) 2007-02-08
AU784495B2 (en) 2006-04-13
AU1600701A (en) 2001-06-06
ES2267587T3 (es) 2007-03-16
KR20090031957A (ko) 2009-03-30
ATE330598T1 (de) 2006-07-15
CA2391277A1 (en) 2001-05-17
US20020187534A1 (en) 2002-12-12
EP1227810B8 (de) 2006-08-16
WO2001034145A1 (en) 2001-05-17
AU2009227836A1 (en) 2009-11-05
KR20020060736A (ko) 2002-07-18
PT1227810E (pt) 2006-11-30

Similar Documents

Publication Publication Date Title
DE60028996D1 (de) Behandlung von krebs durch erhöhung des malonyl-coa-spiegels
Gao et al. Stress granule: A promising target for cancer treatment
Kolbe et al. 4‐n‐butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation
Chao et al. A rthrophytum scoparium inhibits melanogenesis through the down‐regulation of tyrosinase and melanogenic gene expressions in B 16 melanoma cells
Abboud et al. Antitumor action of amygdalin on human breast cancer cells by selective sensitization to oxidative stress
Baek et al. Sesamol decreases melanin biosynthesis in melanocyte cells and zebrafish: Possible involvement of MITF via the intracellular cAMP and p38/JNK signalling pathways
Wallace The polyamines: past, present and future
Gogebakan et al. Role of propolis on tyrosine hydroxylase activity and blood pressure in nitric oxide synthase-inhibited hypertensive rats
Haque et al. The GCN5: its biological functions and therapeutic potentials
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
DE60233650D1 (de) Verfahren zur behandlung von stoffwechselerkrankungen mit malonyl-coa-decarboxylase-hemmern
MA27609A1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
ATE509014T1 (de) Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
ATE487475T1 (de) Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer
Genovés et al. Pentoxifylline in liver ischemia and reperfusion
ATE341539T1 (de) Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
Chen et al. Antiphotoaging effect of boiled abalone residual peptide ATPGDEG on UVB-induced keratinocyte HaCaT cells
NO20020829L (no) Ny anvendelse av docetaxel for behandling av hepatoma
EA200601471A1 (ru) Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты)
Durak et al. Protective and therapeutic effects of molsidomine on radiation induced neural injury in rats
DE60140964D1 (en) Sphingolipiden
DK1565176T3 (da) Middel med ödelæggende virkning på maligne rumorer samt fremgangsmåde til fremstilling heraf
Kashyap et al. Efficacy of selinexor is dependent on IκB-α expression and NF-kb deactivation in multiple myeloma cells
ATE423772T1 (de) Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, B

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee